We are monitoring the impact of COVID-19 on Europe Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1338
Share on
Share on

Europe Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode Of Administration, End Users, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1338
Pages: 132

Europe Cancer Immunotherapy Market Size (2021 to 2026)

The cancer immunotherapy market in Europe is predicted to be growing at a CAGR of 12.45% from 2021 to 2026. The market size is expected to be worth USD 42.30 billion by 2026 from USD 23.52 billion in 2021.

MARKET DRIVERS:

Y-O-Y growth in the prevalence of cancer among EU countries, changing lifestyles, excess intake of alcohol and smoking, high efficiency of immunotherapy when compared to other treatments, few side effects associated with cancer immunotherapy that reduce the chance of recurrence of cancer are the factors that drive the Europe cancer immunotherapy market.

A mounting number of cancer patients and a rising old people population also drive market growth. Furthermore, the rising commonness of cancer is even driving the European Cancer Immunotherapy Market growth. Numerous healthcare facilities and various national government fund schemes are expected to drive the cancer immunotherapy market in Europe.

Increasing opportunities in the existing markets and immunotherapy as an alternative to chemotherapy for the first-line treatment will be market drivers in the future. Treatment-Free Survival (TFS) provides an essential opportunity for patients and their families to resume their activities, travel, and generally approach their daily lives free from ongoing cancer treatment. Another opportunity is that patients in their last stage face the possibility of dying from cancer often value receiving a novel therapy that offers long-term disease control in a small percentage of patients.

MARKET RESTRAINTS:

Factors like the high cost of immunotherapy treatment and the high reducing rate of the product development cycle hamper the market growth. Time is also one of the factors that are hampering the regional market boom. In addition, the cost of cancer therapy treatment and the availability of very little information are the factors challenging the European market. Another problem is disturbing the immune balance intending to restore the potent anti-tumor response that might induce resistance. Still, many challenges exist and have to be overcome to make them available to cancer patients who need immune intervention.

This research report on the European Cancer Immunotherapy has been segmented & sub-segmented into the following categories:

By Type of Therapies: 

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

By Area of Therapy: 

  • Blood Cancer
  • Prostate Cancer
  • Melanoma
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Minor Areas

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European market had accounted for the second-largest market share in the global immunotherapy market in 2020 and holds positive growth along the foreseen period, and is supposed to reach a 12.45% growth rate by the end of 2026. Therefore, this region is presumed to witness a noticeable increase in the upcoming years. In Europe, Germany is the most prominent market driving the area and is assumed to experience a growth rate of about 9% in 2026. The European market is becoming apparent rapidly due to the increasing number of cancer patients in this region. In addition, the rapid increase of advanced treatment facilities paired up with the availability of skilled professionals and support from the government for R&D further boosts the regional business.

KEY MARKET PARTICIPANTS:

A few notable companies operating in the European cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  2. Europe Breast Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Lung Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Melanoma Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Head & Neck Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Prostate Market, By Region, From 2021 to 2026 (USD Million)
  8. Europe Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  9. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Checkpoint inhibitors/immune modulators Market, By Region, From 2021 to 2026 (USD Million)
  11. Europe Therapeutic cancer vaccines Market, By Region, From 2021 to 2026 (USD Million)
  12. Europe Oncolytic virus immunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Cytokines Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Adoptive T cell Transfer Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Adjuvant immunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  16. Europe Interferons Market, By Region, From 2021 to 2026 (USD Million)
  17. Europe Interleukins Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe BCG Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  20. Europe Intravenous Market, By Region, From 2021 to 2026 (USD Million)
  21. Europe Oral Market, By Region, From 2021 to 2026 (USD Million)
  22. Europe Topical Market, By Region, From 2021 to 2026 (USD Million)
  23. Europe Intravesical Market, By Region, From 2021 to 2026 (USD Million)
  24. Europe Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Million)
  25. Europe hospitals Market, By Region, From 2021 to 2026 (USD Million)
  26. Europe Clinics Market, By Region, From 2021 to 2026 (USD Million)
  27. U.K. Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  28. U.K. Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  29. U.K. Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  30. U.K. Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Million)
  31. Germany Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  32. Germany Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  33. Germany Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  34. Germany Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Million)
  35. France Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  36. France Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  37. France Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  38. France Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Million)
  39. Italy Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  40. Italy Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  41. Italy Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  42. Italy Cancer Immunotherapy Market, By End users, From 2021 to 2026 (USD Million)
  43. Spain Cancer Immunotherapy Market, By Application, From 2021 to 2026 (USD Million)
  44. Spain Cancer Immunotherapy Market, By Product Type, From 2021 to 2026 (USD Million)
  45. Spain Cancer Immunotherapy Market, By Mode of Administration, From 2021 to 2026 (USD Million)
  46. Spain Cancer Immunotherapy Market, By End-users, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample